[go: up one dir, main page]

PE20211290A1 - Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson - Google Patents

Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson

Info

Publication number
PE20211290A1
PE20211290A1 PE2020000566A PE2020000566A PE20211290A1 PE 20211290 A1 PE20211290 A1 PE 20211290A1 PE 2020000566 A PE2020000566 A PE 2020000566A PE 2020000566 A PE2020000566 A PE 2020000566A PE 20211290 A1 PE20211290 A1 PE 20211290A1
Authority
PE
Peru
Prior art keywords
disease
parkinson
treatment
propyl
propharmacs
Prior art date
Application number
PE2020000566A
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Lisbet Kværnø
Martin Juhl
Morten Jørgensen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PE20211290A1 publication Critical patent/PE20211290A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (Id) QUE SON PROFARMACOS DEL AGONISTA DE DOPAMINA (4AR,10AR)-1-N-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDRO-BENZO[G]QUINOLINA-6,7-DIOL DONDE R1 Y R2 SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: ACIDO (2S,3S,4S,5R,6S)-3,4,5-TRIHIDROXI-6-(((4AR,10AR)-7-HIDROXI-1-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDROBENZO[G]QUINOLIN-6-IL)OXI)TETRAHIDRO-2H-PIRAN-2-CARBOXILICO; ACIDO (2S,2'S,3S,3'S,4S,4'S,5R,5'R,6S,6'S)-6,6'-(((4AR,10AR)-1-PROPIL-1,2,3,4,4A,5,10,10A-OCTAHIDROBENZO[G]QUINOLINO-6,7-DIIL)BIS(OXI))BIS(3,4,5-TRIHIDROXITETRAHIDRO-2H-PIRAN-2-CARBOXILICO); ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, SINDROME DE LAS PIERNAS INQUIETAS, ENFERMEDAD DE ALZHEIMER.
PE2020000566A 2017-11-24 2018-11-23 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson PE20211290A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24
PCT/EP2018/082361 WO2019101917A1 (en) 2017-11-24 2018-11-23 New catecholamine prodrugs for use in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PE20211290A1 true PE20211290A1 (es) 2021-07-20

Family

ID=64661284

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000566A PE20211290A1 (es) 2017-11-24 2018-11-23 Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson

Country Status (25)

Country Link
US (5) US10729710B2 (es)
EP (1) EP3713933A1 (es)
JP (4) JP7320507B2 (es)
KR (1) KR102712887B1 (es)
CN (3) CN111386267B (es)
AR (1) AR113908A1 (es)
AU (2) AU2018371193B2 (es)
BR (1) BR112019014981A2 (es)
CA (1) CA3082757A1 (es)
CL (1) CL2020001343A1 (es)
CO (1) CO2020006224A2 (es)
CR (1) CR20200225A (es)
EA (1) EA202090987A8 (es)
EC (1) ECSP20030074A (es)
GE (2) GEP20227446B (es)
IL (1) IL274648B2 (es)
JO (1) JOP20200114A1 (es)
MA (1) MA50800A (es)
MX (2) MX2020005366A (es)
PE (1) PE20211290A1 (es)
PH (1) PH12020550631A1 (es)
SG (1) SG11202004461YA (es)
TW (1) TWI816716B (es)
UA (1) UA127575C2 (es)
WO (1) WO2019101917A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111386267B (zh) * 2017-11-24 2023-12-12 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
JP7641234B2 (ja) * 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
CN113727974B (zh) 2019-05-21 2025-01-07 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP7514859B2 (ja) * 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US20250282733A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab Novel 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and uses thereof
US20250282732A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
DE3280252D1 (de) 1981-10-16 1990-10-31 Sandoz Ag 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolin-derivate mit pharmazeutischer wirkung.
FR2540112B1 (fr) 1983-02-01 1986-08-29 Sandoz Sa Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
KR20030036157A (ko) 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
MXPA03001272A (es) 2000-08-11 2004-04-02 Purdue Research Foundation Procedimiento para la preparacion de dinapsolina.
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
JP2005504758A (ja) 2001-08-10 2005-02-17 パーデュー・リサーチ・ファウンデーション キラル・ジナプソリン
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
AU2003223304A1 (en) 2002-03-19 2003-10-08 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
CA2550650A1 (en) 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
WO2006012640A2 (en) 2004-07-21 2006-02-02 Darpharma, Inc. Method of administration of dopamine receptor agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
EP2303851A1 (en) 2008-06-27 2011-04-06 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201036949A (en) 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP3445346A1 (en) 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
CN111386267B (zh) 2017-11-24 2023-12-12 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727974B (zh) 2019-05-21 2025-01-07 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7693430B2 (ja) * 2021-07-15 2025-06-17 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
BR112019014981A2 (pt) 2020-04-07
CL2020001343A1 (es) 2020-09-25
EP3713933A1 (en) 2020-09-30
EA202090987A8 (ru) 2020-09-29
MX2020005366A (es) 2020-08-13
CN117599073A (zh) 2024-02-27
CN111386267B (zh) 2023-12-12
JP2023145580A (ja) 2023-10-11
JP7320507B2 (ja) 2023-08-03
TWI816716B (zh) 2023-10-01
MA50800A (fr) 2020-09-30
RU2020116419A (ru) 2021-12-27
GEP20227446B (en) 2022-12-12
GEAP202215342A (en) 2022-07-11
CO2020006224A2 (es) 2020-05-29
KR20200092955A (ko) 2020-08-04
TW201924693A (zh) 2019-07-01
CN111386267A (zh) 2020-07-07
CR20200225A (es) 2020-07-25
IL274648A (en) 2020-06-30
IL274648B1 (en) 2024-06-01
MX2022016276A (es) 2023-02-09
IL274648B2 (en) 2024-10-01
CA3082757A1 (en) 2019-05-31
AU2023201741A1 (en) 2023-04-20
UA127575C2 (uk) 2023-10-18
US20200338102A1 (en) 2020-10-29
PH12020550631A1 (en) 2021-02-22
US10729710B2 (en) 2020-08-04
US20190160083A1 (en) 2019-05-30
JOP20200114A1 (ar) 2020-05-17
US20240156851A1 (en) 2024-05-16
US12226428B2 (en) 2025-02-18
SG11202004461YA (en) 2020-06-29
JP7320684B2 (ja) 2023-08-03
AR113908A1 (es) 2020-06-24
US20220257623A1 (en) 2022-08-18
US11110110B2 (en) 2021-09-07
US11707476B2 (en) 2023-07-25
US20250381208A1 (en) 2025-12-18
ECSP20030074A (es) 2020-07-31
AU2018371193B2 (en) 2022-12-22
CN117653649A (zh) 2024-03-08
EA202090987A1 (ru) 2020-08-07
AU2018371193A1 (en) 2020-06-11
JP2021504345A (ja) 2021-02-15
JP2023145579A (ja) 2023-10-11
JP7443606B2 (ja) 2024-03-05
KR102712887B1 (ko) 2024-10-02
WO2019101917A1 (en) 2019-05-31
JP2023055830A (ja) 2023-04-18
NZ764717A (en) 2024-08-30

Similar Documents

Publication Publication Date Title
PE20211290A1 (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
ECSP12011631A (es) Composición de insulina de acción prolongada
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO6341623A2 (es) Compuestos organicos
ECSP14004812A (es) Triazolopiridinas sustituidas
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CO6270324A2 (es) Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
UY29988A1 (es) Compuestos de oxazolidinona y su uso como potenciadores del receptor metabotrópico de glutamato
ECSP11010816A (es) Nuevos Compuestos
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
ECSP14026432A (es) (r)-nifuratel y síntesis de (r) y (s)-nifuratel
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
AR116001A2 (es) Composición farmacéutica 271
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
CO6290768A2 (es) Tiazolil-dihidro-indazoles